Manabesh Nath
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Manabesh Nath has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Shubham Misra
Department of Neurology, Yale School of Medicine, New Haven, CT
13 shared publications - Deepti Vibha
Department of Neurology, All India Institute of Medical Sciences, New Delhi, India
12 shared publications - Pradeep Kumar
Clinical Research Unit, All India Institute of Medical Sciences, New Delhi, India
12 shared publications Amit Kumar
Department of Neurology All India Institute of Medical Sciences New Delhi India
3 shared publications- Amit Kumar
Department of Neurology , Post Graduate Institute of Medical Education and Research, PGIMER, Chandigarh, India
3 shared publications - Awadh Kishor Pandit
Department of Neurology, All India Institute of Medical Sciences, New Delhi, India
3 shared publications
Latest Publications
- 13 October 2026
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. -1 (aop)
Outcomes in Patients with Tuberculous Meningitis: A Prospective Cohort Study in North India
: Tuberculous meningitis (TBM) is the most severe form of extrapulmonary tuberculosis, carrying the highest mortality among all forms. This multicentric prospective cohort study conducted in North India aimed to determine the incidence of complications, functional outcome (modified Rankin scale [mRS]), and mortality in TBM. Patients 12 years old and older with TBM were followed up until completion of 9 months of antitubercular treatment. Patients with concomitant HIV infection, other infections causing meningitis, or multidrug-resistant tuberculosis were excluded. The primary outcome was mRS at 9 months. Secondary outcomes included mRS at 6 months, poor mRS (>2), Barthel Index, and mortality at 6 and 9 months. Between October 1, 2019 and March 31, 2024, 585 eligible patients were enrolled, of whom 495 (84.6%) completed follow-up. The median age was 24.0 years old, and the majority were female ( n = 304/495; 61.4%). Complications were present in 377 patients (76.2%): focal neurological deficits (41.6%), seizures (38.6%), immune reconstitution inflammatory syndrome (32.7%), hydrocephalus (24.8%), and drug-induced liver injury (14.1%). Complications were associated with worse mRS on unadjusted analysis (odds ratio [OR]: 2.5 [1.7–3.7]; P P = 0.30). The median mRS improved from 4.0 at presentation to 2.0 at 6 months and 1.0 at 9 months. Death occurred at a median of 91.0 days after presentation. Mortality at 6 months was 9.3% and at 9 months was 10.7%.
- 13 October 2026
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. -1 (aop)
Outcomes in Patients with Tuberculous Meningitis: A Prospective Cohort Study in North India
: Tuberculous meningitis (TBM) is the most severe form of extrapulmonary tuberculosis, carrying the highest mortality among all forms. This multicentric prospective cohort study conducted in North India aimed to determine the incidence of complications, functional outcome (modified Rankin scale [mRS]), and mortality in TBM. Patients 12 years old and older with TBM were followed up until completion of 9 months of antitubercular treatment. Patients with concomitant HIV infection, other infections causing meningitis, or multidrug-resistant tuberculosis were excluded. The primary outcome was mRS at 9 months. Secondary outcomes included mRS at 6 months, poor mRS (>2), Barthel Index, and mortality at 6 and 9 months. Between October 1, 2019 and March 31, 2024, 585 eligible patients were enrolled, of whom 495 (84.6%) completed follow-up. The median age was 24.0 years old, and the majority were female ( n = 304/495; 61.4%). Complications were present in 377 patients (76.2%): focal neurological deficits (41.6%), seizures (38.6%), immune reconstitution inflammatory syndrome (32.7%), hydrocephalus (24.8%), and drug-induced liver injury (14.1%). Complications were associated with worse mRS on unadjusted analysis (odds ratio [OR]: 2.5 [1.7–3.7]; P P = 0.30). The median mRS improved from 4.0 at presentation to 2.0 at 6 months and 1.0 at 9 months. Death occurred at a median of 91.0 days after presentation. Mortality at 6 months was 9.3% and at 9 months was 10.7%.
- Open Access
Evolving Epidemiology of Stroke in India: Burden, Inequalities, and Risk Factors from 1990 to 2023 with Projections to 2035
Background and Purpose: Stroke continues to be one of the major causes of death and long-term disability worldwide, with a greater impact in low- and middle-income countries. In India, there is limited evidence examining stroke burden and its changes over time and across regions. Therefore, we aimed to assess the burden of stroke in India from 1990 to 2023 using the latest data from the Global Burden of Disease (GBD) Study, along with projections up to 2035. Methods: We used estimates from the GBD 2023 study to examine stroke incidence, prevalence, mortality, and disability-adjusted life years (DALYs) in India from 1990 to 2023. Age-standardized rates were analyzed to understand how these measures have changed over time. We also conducted state-level analyses to explore regional differences in stroke burden. The contributions of all major modifiable risk factors were assessed using population-attributable fractions. In addition, we projected future trends in stroke burden up to 2035. Results: From 1990 to 2023, the percentage change in overall stroke burden in India showed minimal variation across key indicators. Incidence remained largely stable (0.00% [–0.04 to 0.05]), while prevalence showed a slight increase (0.06% [0.03 to 0.10]). Mortality (–0.11% [–0.36 to 0.20]) and DALYs (–0.17% [–0.38 to 0.12]) demonstrated modest declines over the study period. Notable regional disparities were evident, with states such as Chhattisgarh, Assam, and Jharkhand bearing the highest burden. High systolic blood pressure remained the leading risk factor in 2023, contributing the largest share of stroke-related deaths, followed by dietary risks, air pollution, tobacco use, and high body mass index. Future projections indicate that by 2035, stroke prevalence is likely to increase, while incidence, mortality, and DALYs are expected to show only modest changes. Conclusions: Stroke remains a major and growing public health challenge in India with a continuing increase in burden despite slight improvements in age-standardized rates over time. Addressing this challenge will require stronger prevention efforts, better control of key risk factors, and focused strategies to reduce regional disparities in stroke burden nationwide.
Open AccessEvolving Epidemiology of Stroke in India: Burden, Inequalities, and Risk Factors from 1990 to 2023 with Projections to 2035
Background and Purpose: Stroke continues to be one of the major causes of death and long-term disability worldwide, with a greater impact in low- and middle-income countries. In India, there is limited evidence examining stroke burden and its changes over time and across regions. Therefore, we aimed to assess the burden of stroke in India from 1990 to 2023 using the latest data from the Global Burden of Disease (GBD) Study, along with projections up to 2035. Methods: We used estimates from the GBD 2023 study to examine stroke incidence, prevalence, mortality, and disability-adjusted life years (DALYs) in India from 1990 to 2023. Age-standardized rates were analyzed to understand how these measures have changed over time. We also conducted state-level analyses to explore regional differences in stroke burden. The contributions of all major modifiable risk factors were assessed using population-attributable fractions. In addition, we projected future trends in stroke burden up to 2035. Results: From 1990 to 2023, the percentage change in overall stroke burden in India showed minimal variation across key indicators. Incidence remained largely stable (0.00% [–0.04 to 0.05]), while prevalence showed a slight increase (0.06% [0.03 to 0.10]). Mortality (–0.11% [–0.36 to 0.20]) and DALYs (–0.17% [–0.38 to 0.12]) demonstrated modest declines over the study period. Notable regional disparities were evident, with states such as Chhattisgarh, Assam, and Jharkhand bearing the highest burden. High systolic blood pressure remained the leading risk factor in 2023, contributing the largest share of stroke-related deaths, followed by dietary risks, air pollution, tobacco use, and high body mass index. Future projections indicate that by 2035, stroke prevalence is likely to increase, while incidence, mortality, and DALYs are expected to show only modest changes. Conclusions: Stroke remains a major and growing public health challenge in India with a continuing increase in burden despite slight improvements in age-standardized rates over time. Addressing this challenge will require stronger prevention efforts, better control of key risk factors, and focused strategies to reduce regional disparities in stroke burden nationwide.
- Open Access
The Great Recanalization Debate in Acute Ischemic Stroke: Direct Thrombectomy versus Bridging Therapy—A Meta-analysis of Randomized Controlled Trials
Background: Endovascular thrombectomy (EVT) is the standard of care for acute ischemic stroke caused by large-vessel occlusion. However, the additional benefit of intravenous thrombolysis (IVT) before EVT remains controversial. This systematic review and meta-analysis evaluated the efficacy and safety of bridging therapy (EVT plus IVT) compared with EVT alone. Methods: This systematic review and meta-analysis was conducted according to PRISMA 2020 and Cochrane Handbook recommendations and prospectively registered in PROSPERO. PubMed, EMbase, Scopus, and the Cochrane Library were searched for randomized controlled trials published between 1 st January 2015 and 30 th April 2026 comparing EVT plus IVT versus EVT alone in acute ischemic stroke. Random-effects meta-analysis was performed to estimate pooled odds ratios (ORs) with 95% confidence intervals (CIs). Primary outcomes included functional independence at 90 days and successful recanalization. Secondary outcomes included symptomatic intracranial hemorrhage (sICH) and all-cause mortality. Results: Eleven randomized controlled trials involving 4,419 patients were included in the meta-analysis. Compared with EVT alone, bridging therapy was associated with significantly better functional independence at 90 days (OR=1.25; 95% CI: 1.02–1.53). Patients receiving EVT plus IVT also demonstrated a trend toward higher rates of successful recanalization (OR=1.25; 95% CI: 0.95–1.64) and lower 90-day mortality (OR=0.84; 95% CI: 0.67–1.04). The risk of sICH was comparable between the two treatment strategies (OR=1.07; 95% CI: 0.81–1.40). Overall, the certainty of evidence was rated as moderate. Conclusions: Bridging therapy before EVT may improve functional outcomes and recanalization without increasing sICH, supporting its use as a reasonable treatment strategy in eligible patients with acute ischemic stroke.
Open AccessThe Great Recanalization Debate in Acute Ischemic Stroke: Direct Thrombectomy versus Bridging Therapy—A Meta-analysis of Randomized Controlled Trials
Background: Endovascular thrombectomy (EVT) is the standard of care for acute ischemic stroke caused by large-vessel occlusion. However, the additional benefit of intravenous thrombolysis (IVT) before EVT remains controversial. This systematic review and meta-analysis evaluated the efficacy and safety of bridging therapy (EVT plus IVT) compared with EVT alone. Methods: This systematic review and meta-analysis was conducted according to PRISMA 2020 and Cochrane Handbook recommendations and prospectively registered in PROSPERO. PubMed, EMbase, Scopus, and the Cochrane Library were searched for randomized controlled trials published between 1 st January 2015 and 30 th April 2026 comparing EVT plus IVT versus EVT alone in acute ischemic stroke. Random-effects meta-analysis was performed to estimate pooled odds ratios (ORs) with 95% confidence intervals (CIs). Primary outcomes included functional independence at 90 days and successful recanalization. Secondary outcomes included symptomatic intracranial hemorrhage (sICH) and all-cause mortality. Results: Eleven randomized controlled trials involving 4,419 patients were included in the meta-analysis. Compared with EVT alone, bridging therapy was associated with significantly better functional independence at 90 days (OR=1.25; 95% CI: 1.02–1.53). Patients receiving EVT plus IVT also demonstrated a trend toward higher rates of successful recanalization (OR=1.25; 95% CI: 0.95–1.64) and lower 90-day mortality (OR=0.84; 95% CI: 0.67–1.04). The risk of sICH was comparable between the two treatment strategies (OR=1.07; 95% CI: 0.81–1.40). Overall, the certainty of evidence was rated as moderate. Conclusions: Bridging therapy before EVT may improve functional outcomes and recanalization without increasing sICH, supporting its use as a reasonable treatment strategy in eligible patients with acute ischemic stroke.
- 7 November 2025
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1) , 1-13
Microbiota Dysbiosis in Amyotrophic Lateral Sclerosis: A Systematic Review of Human Studies
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by progressive motor neuron degeneration. Despite intensive research, its pathogenesis remains poorly understood. Recent insights suggest a pivotal role of the gut microbiota in modulating neuroinflammation and neurodegeneration via the gut-brain axis. This systematic review aims to synthesize clinical evidence on gut microbiota dysbiosis in ALS, exploring microbial and metabolic alterations and their associations with disease progression and severity. A comprehensive literature search was conducted across PubMed, Embase, Scopus, Web of Science, and other databases up to May 10, 2024, adhering to PRISMA 2020 guidelines. Eighteen eligible human studies were selected based on predefined inclusion criteria. Data on microbial diversity, taxonomic shifts, metabolite profiles, and clinical correlations were extracted and assessed using a modified Newcastle–Ottawa Scale. Most studies reported altered microbial diversity, reduced butyrate-producing bacteria (e.g., Faecalibacterium, Roseburia), and increased pro-inflammatory taxa (e.g., Escherichia coli, Bacteroides) in ALS. Integrated microbiome–metabolome analyses revealed disruptions in SCFAs, bile acids, and lipid metabolism, some correlating with ALSFRS-R scores and cognitive impairment. Although some studies showed minimal or no differences, the overall evidence supports a link between dysbiosis and ALS pathophysiology. Probiotic trials demonstrated limited efficacy, highlighting the need for targeted, patient-specific interventions. Gut microbiota dysbiosis is increasingly recognized as a contributor to ALS progression. However, methodological variability, small sample sizes, and limited longitudinal data restrict definitive conclusions. Future research should employ standardized, multi-omics approaches and larger cohorts to clarify causal links and develop microbiome-informed diagnostics and therapies for ALS. Graphical Abstract
- 7 November 2025
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1) , 1-13
Microbiota Dysbiosis in Amyotrophic Lateral Sclerosis: A Systematic Review of Human Studies
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by progressive motor neuron degeneration. Despite intensive research, its pathogenesis remains poorly understood. Recent insights suggest a pivotal role of the gut microbiota in modulating neuroinflammation and neurodegeneration via the gut-brain axis. This systematic review aims to synthesize clinical evidence on gut microbiota dysbiosis in ALS, exploring microbial and metabolic alterations and their associations with disease progression and severity. A comprehensive literature search was conducted across PubMed, Embase, Scopus, Web of Science, and other databases up to May 10, 2024, adhering to PRISMA 2020 guidelines. Eighteen eligible human studies were selected based on predefined inclusion criteria. Data on microbial diversity, taxonomic shifts, metabolite profiles, and clinical correlations were extracted and assessed using a modified Newcastle–Ottawa Scale. Most studies reported altered microbial diversity, reduced butyrate-producing bacteria (e.g., Faecalibacterium, Roseburia), and increased pro-inflammatory taxa (e.g., Escherichia coli, Bacteroides) in ALS. Integrated microbiome–metabolome analyses revealed disruptions in SCFAs, bile acids, and lipid metabolism, some correlating with ALSFRS-R scores and cognitive impairment. Although some studies showed minimal or no differences, the overall evidence supports a link between dysbiosis and ALS pathophysiology. Probiotic trials demonstrated limited efficacy, highlighting the need for targeted, patient-specific interventions. Gut microbiota dysbiosis is increasingly recognized as a contributor to ALS progression. However, methodological variability, small sample sizes, and limited longitudinal data restrict definitive conclusions. Future research should employ standardized, multi-omics approaches and larger cohorts to clarify causal links and develop microbiome-informed diagnostics and therapies for ALS. Graphical Abstract
- 10 December 2024
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 55 (4) , e14372
Subtyping strokes using blood‐based protein biomarkers: A high‐throughput proteomics and machine learning approach
Background: Rapid diagnosis of stroke and its subtypes is critical in early stages. We aimed to discover and validate blood‐based protein biomarkers to differentiate ischemic stroke (IS) from intracerebral haemorrhage (ICH) using high‐throughput proteomics.Methods: We collected serum samples within 24 h from acute stroke (IS & ICH) and mimics patients. In the discovery phase, SWATH‐MS proteomics identified differentially expressed proteins, which were validated using targeted proteomics in the validation phase. We conducted interaction network and pathway analyses using Cytoscape 3.10.0. We determined cut‐off points using the Youden Index. We developed three prediction models using multivariable logistic regression analyses. We assessed the model performance using statistical tests.Results: We included 20 IS and 20 ICH in the discovery phase and 150 IS, 150 ICH, and six stroke mimics in the validation phase. We quantified 375 proteins using SWATH‐MS. Between IS and ICH, we discovered 20 differentially expressed proteins. In the validation phase, the combined prediction model including three biomarkers: GFAP (aOR 0.04; 95%CI .02–.11), MMP‐9 (aOR .09; .03–.28), APO‐C1 (aOR 5.76; 2.66–12.47) and clinical variables independently differentiated IS from ICH (accuracy: 92%, negative predictive value: 94%). Adding biomarkers to clinical variables improved discrimination by 26% (p < .001). Additionally, nine biomarkers differentiated IS from ICH within 6 h, while three biomarkers differentiated IS from mimics.Conclusions: Our study demonstrated that GFAP, MMP‐9 and APO‐C1 biomarkers independently differentiated IS from ICH within 24 h and significantly improved the discrimination ability of prediction models. Temporal profiling of these biomarkers in the acute phase of stroke is warranted.
- 10 December 2024
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 55 (4) , e14372
Subtyping strokes using blood‐based protein biomarkers: A high‐throughput proteomics and machine learning approach
Background: Rapid diagnosis of stroke and its subtypes is critical in early stages. We aimed to discover and validate blood‐based protein biomarkers to differentiate ischemic stroke (IS) from intracerebral haemorrhage (ICH) using high‐throughput proteomics.Methods: We collected serum samples within 24 h from acute stroke (IS & ICH) and mimics patients. In the discovery phase, SWATH‐MS proteomics identified differentially expressed proteins, which were validated using targeted proteomics in the validation phase. We conducted interaction network and pathway analyses using Cytoscape 3.10.0. We determined cut‐off points using the Youden Index. We developed three prediction models using multivariable logistic regression analyses. We assessed the model performance using statistical tests.Results: We included 20 IS and 20 ICH in the discovery phase and 150 IS, 150 ICH, and six stroke mimics in the validation phase. We quantified 375 proteins using SWATH‐MS. Between IS and ICH, we discovered 20 differentially expressed proteins. In the validation phase, the combined prediction model including three biomarkers: GFAP (aOR 0.04; 95%CI .02–.11), MMP‐9 (aOR .09; .03–.28), APO‐C1 (aOR 5.76; 2.66–12.47) and clinical variables independently differentiated IS from ICH (accuracy: 92%, negative predictive value: 94%). Adding biomarkers to clinical variables improved discrimination by 26% (p < .001). Additionally, nine biomarkers differentiated IS from ICH within 6 h, while three biomarkers differentiated IS from mimics.Conclusions: Our study demonstrated that GFAP, MMP‐9 and APO‐C1 biomarkers independently differentiated IS from ICH within 24 h and significantly improved the discrimination ability of prediction models. Temporal profiling of these biomarkers in the acute phase of stroke is warranted.
- Open Access
Evaluating Thrombectomy Devices and Combination Therapies in Acute ischemic Stroke: A systematic review & Network Meta-Analysis of 201 studies
Background and Objective: Mechanical Thrombectomy (MT) has become the standard treatment for acute ischemic stroke (AIS) caused by large vessel occlusion (LVO). However, the relative efficacy and safety of different MT devices remain uncertain. To evaluate and compare the safety and efficacy of different Thrombectomy devices and combination therapies in acute ischemic stroke, utilizing a network meta-analysis. Methods: Patients receiving different MT devices (MERCI, TREVO, Solitaire, Penumbra, or a combination of MT devices) compared to Standard Care or Intravenous Thrombolysis (IVT), or Intra-arterial Thrombolysis (IAT) for AIS treatment. Safety outcomes were symptomatic intracranial hemorrhage (sICH) and all-cause mortality at 90 days. Efficacy outcome were good functional recovery at 90 days (defined as a modified Rankin Scale score of 0–2) and successful recanalization (measured by a TICI score of 2b-3). Results: We included 201 studies, comprising 43 RCTs and 159 cohort studies with 71,154 AIS patients. TREVO device demonstrated the highest efficacy for functional recovery (OR=3.63, 95% CrI: 2.45–5.43), followed by MT + IVT (OR=2.87, CrI: 2.30–3.59). TREVO also achieved the highest rate of successful recanalization (OR 3.35, CrI: 1.36–8.19). MERCI, Solitaire and Aspiration devices were linked to a higher risk of sICH. For all-cause mortality at 90 days, TREVO notably reduced the odds (OR=0.56, CrI: 0.37–0.86), whereas aspiration devices showed no significant difference from standard treatments. Conclusion: Our findings demonstrate contemporary stent-retriever device technology as the most effective option for improving functional recovery, recanalization success, and reducing mortality in AIS patients. These results highlight the critical need for selecting the most effective and safest thrombectomy device to optimize outcomes in acute stroke care.
Open AccessEvaluating Thrombectomy Devices and Combination Therapies in Acute ischemic Stroke: A systematic review & Network Meta-Analysis of 201 studies
Background and Objective: Mechanical Thrombectomy (MT) has become the standard treatment for acute ischemic stroke (AIS) caused by large vessel occlusion (LVO). However, the relative efficacy and safety of different MT devices remain uncertain. To evaluate and compare the safety and efficacy of different Thrombectomy devices and combination therapies in acute ischemic stroke, utilizing a network meta-analysis. Methods: Patients receiving different MT devices (MERCI, TREVO, Solitaire, Penumbra, or a combination of MT devices) compared to Standard Care or Intravenous Thrombolysis (IVT), or Intra-arterial Thrombolysis (IAT) for AIS treatment. Safety outcomes were symptomatic intracranial hemorrhage (sICH) and all-cause mortality at 90 days. Efficacy outcome were good functional recovery at 90 days (defined as a modified Rankin Scale score of 0–2) and successful recanalization (measured by a TICI score of 2b-3). Results: We included 201 studies, comprising 43 RCTs and 159 cohort studies with 71,154 AIS patients. TREVO device demonstrated the highest efficacy for functional recovery (OR=3.63, 95% CrI: 2.45–5.43), followed by MT + IVT (OR=2.87, CrI: 2.30–3.59). TREVO also achieved the highest rate of successful recanalization (OR 3.35, CrI: 1.36–8.19). MERCI, Solitaire and Aspiration devices were linked to a higher risk of sICH. For all-cause mortality at 90 days, TREVO notably reduced the odds (OR=0.56, CrI: 0.37–0.86), whereas aspiration devices showed no significant difference from standard treatments. Conclusion: Our findings demonstrate contemporary stent-retriever device technology as the most effective option for improving functional recovery, recanalization success, and reducing mortality in AIS patients. These results highlight the critical need for selecting the most effective and safest thrombectomy device to optimize outcomes in acute stroke care.
- Open Access
- 3 June 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (6) , e0296616
Prognostic biomarkers of intracerebral hemorrhage identified using targeted proteomics and machine learning algorithms
Early prognostication of patient outcomes in intracerebral hemorrhage (ICH) is critical for patient care. We aim to investigate protein biomarkers’ role in prognosticating outcomes in ICH patients. We assessed 22 protein biomarkers using targeted proteomics in serum samples obtained from the ICH patient dataset (N = 150). We defined poor outcomes as modified Rankin scale score of 3–6. We incorporated clinical variables and protein biomarkers in regression models and random forest-based machine learning algorithms to predict poor outcomes and mortality. We report Odds Ratio (OR) or Hazard Ratio (HR) with 95% Confidence Interval (CI). We used five-fold cross-validation and bootstrapping for internal validation of prediction models. We included 149 patients for 90-day and 144 patients with ICH for 180-day outcome analyses. In multivariable logistic regression, UCH-L1 (adjusted OR 9.23; 95%CI 2.41–35.33), alpha-2-macroglobulin (aOR 5.57; 95%CI 1.26–24.59), and Serpin-A11 (aOR 9.33; 95%CI 1.09–79.94) were independent predictors of 90-day poor outcome; MMP-2 (aOR 6.32; 95%CI 1.82–21.90) was independent predictor of 180-day poor outcome. In multivariable Cox regression models, IGFBP-3 (aHR 2.08; 95%CI 1.24–3.48) predicted 90-day and MMP-9 (aOR 1.98; 95%CI 1.19–3.32) predicted 180-day mortality. Machine learning identified additional predictors, including haptoglobin for poor outcomes and UCH-L1, APO-C1, and MMP-2 for mortality prediction. Overall, random forest models outperformed regression models for predicting 180-day poor outcomes (AUC 0.89), and 90-day (AUC 0.81) and 180-day mortality (AUC 0.81). Serum biomarkers independently predicted short-term poor outcomes and mortality after ICH. Further research utilizing a multi-omics platform and temporal profiling is needed to explore additional biomarkers and refine predictive models for ICH prognosis.
- 3 June 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (6) , e0296616
Open AccessPrognostic biomarkers of intracerebral hemorrhage identified using targeted proteomics and machine learning algorithms
Early prognostication of patient outcomes in intracerebral hemorrhage (ICH) is critical for patient care. We aim to investigate protein biomarkers’ role in prognosticating outcomes in ICH patients. We assessed 22 protein biomarkers using targeted proteomics in serum samples obtained from the ICH patient dataset (N = 150). We defined poor outcomes as modified Rankin scale score of 3–6. We incorporated clinical variables and protein biomarkers in regression models and random forest-based machine learning algorithms to predict poor outcomes and mortality. We report Odds Ratio (OR) or Hazard Ratio (HR) with 95% Confidence Interval (CI). We used five-fold cross-validation and bootstrapping for internal validation of prediction models. We included 149 patients for 90-day and 144 patients with ICH for 180-day outcome analyses. In multivariable logistic regression, UCH-L1 (adjusted OR 9.23; 95%CI 2.41–35.33), alpha-2-macroglobulin (aOR 5.57; 95%CI 1.26–24.59), and Serpin-A11 (aOR 9.33; 95%CI 1.09–79.94) were independent predictors of 90-day poor outcome; MMP-2 (aOR 6.32; 95%CI 1.82–21.90) was independent predictor of 180-day poor outcome. In multivariable Cox regression models, IGFBP-3 (aHR 2.08; 95%CI 1.24–3.48) predicted 90-day and MMP-9 (aOR 1.98; 95%CI 1.19–3.32) predicted 180-day mortality. Machine learning identified additional predictors, including haptoglobin for poor outcomes and UCH-L1, APO-C1, and MMP-2 for mortality prediction. Overall, random forest models outperformed regression models for predicting 180-day poor outcomes (AUC 0.89), and 90-day (AUC 0.81) and 180-day mortality (AUC 0.81). Serum biomarkers independently predicted short-term poor outcomes and mortality after ICH. Further research utilizing a multi-omics platform and temporal profiling is needed to explore additional biomarkers and refine predictive models for ICH prognosis.
- 30 January 2024
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 54 (6) , e14165
From A to E: Uniting vitamins against stroke risk—A systematic review and network meta‐analysis
Background and Aim: Stroke represents a significant public health challenge, necessitating the exploration of preventive measures. This network meta‐analysis aimed to assess the efficacy of different vitamin treatments compared to a placebo in preventing stroke.Methods: A systematic electronic search in databases including PubMed, EmBASE, Web of Science, clinicaltrials.gov, and Google Scholar until 31 May 2023 was conducted, to identify published studies investigating the association between vitamin intake and the risk of stroke. Pooled risk ratio (RR) with 95% confidence intervals (CIs) was calculated using a frequentist network meta‐analysis. Furthermore, we ranked vitamins based on p‐scores, facilitating a comparative assessment of their effectiveness in preventing stroke.Results: A total of 56 studies, including 17 randomized controlled trials (RCTs) and 39 cohort studies were analyzed. Direct estimates obtained from network meta‐analysis, we found that vitamin A (RR: .81 [.72–.91]), vitamin B‐complex (RR: .85 [.74–.97]), vitamin B6 (RR: 79 [.68–.92]), folate (RR: .86 [.75–.97]), vitamin C (RR: .77 [.70–.85]) and vitamin D (RR: .73 [.64–.83]) were significantly associated with a decreased stroke risk. However, no significant association was observed for vitamin B2, vitamin B12, and vitamin E. Subsequent to network meta‐analysis, vitamins were ranked in decreasing order of their efficacy in stroke prevention based on p‐score, with vitamin D (p‐score = .91), vitamin C (p‐score = .79), vitamin B6 (p‐score = .70), vitamin A (p‐score = .65), vitamin B‐complex (p‐score = .53), folate (p‐score = .49), vitamin B2 (p‐score = .39), vitamin E (p‐score = .28), vitamin B12 (.13) and placebo (.10).Conclusion: Our study has established noteworthy connections between vitamin A, vitamin B‐complex, vitamin B6, folate, vitamin C, and vitamin D in the realm of stroke prevention. These findings add substantial weight to the accumulating evidence supporting the potential advantages of vitamin interventions in mitigating the risk of stroke. However, to solidify and validate these observations, additional research is imperative. Well‐designed clinical trials or cohort studies are needed to further explore these associations and formulate clear guidelines for incorporating vitamin supplementation into effective stroke prevention strategies.
- 30 January 2024
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 54 (6) , e14165
From A to E: Uniting vitamins against stroke risk—A systematic review and network meta‐analysis
Background and Aim: Stroke represents a significant public health challenge, necessitating the exploration of preventive measures. This network meta‐analysis aimed to assess the efficacy of different vitamin treatments compared to a placebo in preventing stroke.Methods: A systematic electronic search in databases including PubMed, EmBASE, Web of Science, clinicaltrials.gov, and Google Scholar until 31 May 2023 was conducted, to identify published studies investigating the association between vitamin intake and the risk of stroke. Pooled risk ratio (RR) with 95% confidence intervals (CIs) was calculated using a frequentist network meta‐analysis. Furthermore, we ranked vitamins based on p‐scores, facilitating a comparative assessment of their effectiveness in preventing stroke.Results: A total of 56 studies, including 17 randomized controlled trials (RCTs) and 39 cohort studies were analyzed. Direct estimates obtained from network meta‐analysis, we found that vitamin A (RR: .81 [.72–.91]), vitamin B‐complex (RR: .85 [.74–.97]), vitamin B6 (RR: 79 [.68–.92]), folate (RR: .86 [.75–.97]), vitamin C (RR: .77 [.70–.85]) and vitamin D (RR: .73 [.64–.83]) were significantly associated with a decreased stroke risk. However, no significant association was observed for vitamin B2, vitamin B12, and vitamin E. Subsequent to network meta‐analysis, vitamins were ranked in decreasing order of their efficacy in stroke prevention based on p‐score, with vitamin D (p‐score = .91), vitamin C (p‐score = .79), vitamin B6 (p‐score = .70), vitamin A (p‐score = .65), vitamin B‐complex (p‐score = .53), folate (p‐score = .49), vitamin B2 (p‐score = .39), vitamin E (p‐score = .28), vitamin B12 (.13) and placebo (.10).Conclusion: Our study has established noteworthy connections between vitamin A, vitamin B‐complex, vitamin B6, folate, vitamin C, and vitamin D in the realm of stroke prevention. These findings add substantial weight to the accumulating evidence supporting the potential advantages of vitamin interventions in mitigating the risk of stroke. However, to solidify and validate these observations, additional research is imperative. Well‐designed clinical trials or cohort studies are needed to further explore these associations and formulate clear guidelines for incorporating vitamin supplementation into effective stroke prevention strategies.
- 2 March 2023
- Published by Springer Nature in Acta Neurologica Belgica
- Vol. 123 (6) , 2085-2110
Phosphodiesterase 4 D (PDE4D) gene polymorphisms and risk of ischemic stroke: A systematic review and meta-analysis
Background and purpose Studies on the relationship between Phosphodiesterase 4 D (PDE4D) gene polymorphism with the risk of ischemic stroke (IS) have shown discordant results. The present meta-analysis was aimed to clarify the relationship between PDE4D gene polymorphism with the risk of IS by estimating pooled analysis of published epidemiological studies. Methods A comprehensive literature search for all the published articles was performed in various electronic databases, including PubMed, EMbase, Cochrane Library, Trip Database, Worldwide Science, CINAHL, and Google Scholar up to 22nd December 2021. Pooled Odds ratios (ORs) with 95% Confidence Intervals (CIs) under dominant, recessive, and allelic models were calculated. Subgroup analysis based on ethnicity (Caucasian vs. Asian) was performed to examine the reliability of these findings. Sensitivity analysis was also performed to detect the heterogeneity between studies. Finally, Begg’s funnel plot was used to assess the potential for publication bias. Results In our meta-analysis, we identified a total of 47 case–control studies with 20,644 ischemic stroke (IS) cases and 23,201 control subjects, including 17 studies of Caucasian descent and 30 studies of Asian descent. Our findings suggest that there was a significant relationship between SNP45 gene polymorphism and risk of IS (Recessive model: OR = 2.06, 95% CI 1.31–3.23), SNP83 overall (allelic model: OR = 1.22, 95% CI 1.04–1.42), Asian (allelic model: OR = 1.20, 95% CI 1.05–1.37), and SNP89 Asian (Dominant model: OR = 1.43, 95% CI 1.29–1.59, recessive model: OR = 1.42, 95% CI 1.28–1.58) respectively. However, no significant relationship was found between SNP32, SNP41, SNP26, SNP56, and SNP87 gene polymorphisms and risk of IS. Conclusion Findings of this meta-analysis conclude that SNP45, SNP83, and SNP89 polymorphism could be capable of increasing stroke susceptibility in Asians but not in the Caucasian population. Genotyping of SNP 45, 83, 89 polymorphisms may be used as a predictor for the occurrence of IS.
- 2 March 2023
- Published by Springer Nature in Acta Neurologica Belgica
- Vol. 123 (6) , 2085-2110
Phosphodiesterase 4 D (PDE4D) gene polymorphisms and risk of ischemic stroke: A systematic review and meta-analysis
Background and purpose Studies on the relationship between Phosphodiesterase 4 D (PDE4D) gene polymorphism with the risk of ischemic stroke (IS) have shown discordant results. The present meta-analysis was aimed to clarify the relationship between PDE4D gene polymorphism with the risk of IS by estimating pooled analysis of published epidemiological studies. Methods A comprehensive literature search for all the published articles was performed in various electronic databases, including PubMed, EMbase, Cochrane Library, Trip Database, Worldwide Science, CINAHL, and Google Scholar up to 22nd December 2021. Pooled Odds ratios (ORs) with 95% Confidence Intervals (CIs) under dominant, recessive, and allelic models were calculated. Subgroup analysis based on ethnicity (Caucasian vs. Asian) was performed to examine the reliability of these findings. Sensitivity analysis was also performed to detect the heterogeneity between studies. Finally, Begg’s funnel plot was used to assess the potential for publication bias. Results In our meta-analysis, we identified a total of 47 case–control studies with 20,644 ischemic stroke (IS) cases and 23,201 control subjects, including 17 studies of Caucasian descent and 30 studies of Asian descent. Our findings suggest that there was a significant relationship between SNP45 gene polymorphism and risk of IS (Recessive model: OR = 2.06, 95% CI 1.31–3.23), SNP83 overall (allelic model: OR = 1.22, 95% CI 1.04–1.42), Asian (allelic model: OR = 1.20, 95% CI 1.05–1.37), and SNP89 Asian (Dominant model: OR = 1.43, 95% CI 1.29–1.59, recessive model: OR = 1.42, 95% CI 1.28–1.58) respectively. However, no significant relationship was found between SNP32, SNP41, SNP26, SNP56, and SNP87 gene polymorphisms and risk of IS. Conclusion Findings of this meta-analysis conclude that SNP45, SNP83, and SNP89 polymorphism could be capable of increasing stroke susceptibility in Asians but not in the Caucasian population. Genotyping of SNP 45, 83, 89 polymorphisms may be used as a predictor for the occurrence of IS.
- 5 January 2023
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 53 (4) , e13944
Decompressive surgery in cerebral venous thrombosis: A systematic review and meta‐analysis
Objective: The efficacy of decompressive surgery (DS) in cerebral venous thrombosis (CVT) patients has been reported in several case reports and case series. We aimed at determining the association of DS compared with medical management and timing of surgery with functional outcome and mortality. We also aimed at determining the prevalence of DS in CVT patients.Methods: The literature search was conducted till 7 November 2022 in PubMed, Google Scholar, EMBASE and Cochrane Library databases. Risk of bias was examined using Joanna Briggs Institute scale for case series and case reports. Association of DS compared with medical management and timing of surgery with functional outcome and mortality was determined using odds ratio (OR) and 95% confidence interval (CI). Pooled prevalence of DS in CVT patients with 95%CI was calculated. Heterogeneity was explored using outlier, meta‐regression, sensitivity and subgroup analyses.Results: Fifty‐one studies consisting of 483 CVT cases with DS were included. The OR of poor outcome with surgery was 0.03; (95%CI: 0.00–0.22) and of mortality with surgery was 0.25; (95%CI: 0.02–2.60) versus that with medical management. Surgery done ≤48 h of admission was significantly associated with less mortality (OR: 0.26; 95%CI: 0.10–0.69). Pooled prevalence of DS in CVT was 12% (95%CI: 8%–17%; I2 = 91%). Revised pooled prevalence after removing outliers was 10% (95%CI: 7%–13%; I2 = 73%).Conclusions: Surgery ≤48 h of admission might decrease mortality in CVT patients and may result in improved functional outcome. Further prospective studies with appropriate control arms are required to confirm its efficacy over medical management.
- 5 January 2023
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 53 (4) , e13944
Decompressive surgery in cerebral venous thrombosis: A systematic review and meta‐analysis
Objective: The efficacy of decompressive surgery (DS) in cerebral venous thrombosis (CVT) patients has been reported in several case reports and case series. We aimed at determining the association of DS compared with medical management and timing of surgery with functional outcome and mortality. We also aimed at determining the prevalence of DS in CVT patients.Methods: The literature search was conducted till 7 November 2022 in PubMed, Google Scholar, EMBASE and Cochrane Library databases. Risk of bias was examined using Joanna Briggs Institute scale for case series and case reports. Association of DS compared with medical management and timing of surgery with functional outcome and mortality was determined using odds ratio (OR) and 95% confidence interval (CI). Pooled prevalence of DS in CVT patients with 95%CI was calculated. Heterogeneity was explored using outlier, meta‐regression, sensitivity and subgroup analyses.Results: Fifty‐one studies consisting of 483 CVT cases with DS were included. The OR of poor outcome with surgery was 0.03; (95%CI: 0.00–0.22) and of mortality with surgery was 0.25; (95%CI: 0.02–2.60) versus that with medical management. Surgery done ≤48 h of admission was significantly associated with less mortality (OR: 0.26; 95%CI: 0.10–0.69). Pooled prevalence of DS in CVT was 12% (95%CI: 8%–17%; I2 = 91%). Revised pooled prevalence after removing outliers was 10% (95%CI: 7%–13%; I2 = 73%).Conclusions: Surgery ≤48 h of admission might decrease mortality in CVT patients and may result in improved functional outcome. Further prospective studies with appropriate control arms are required to confirm its efficacy over medical management.